Prolight Diagnostics
0.168
SEK
+3.7 %
PRLD
Nordic SME
Medical Equipment & Services
Health Care
Be the first to follow this company
+3.7%
+3.07%
-29.71%
+18.31%
-44.19%
-50%
-85.86%
-90.4%
-60.93%
www.prolightdiagnostics.se/investor-relations
Prolight Diagnostics develops test systems in POCT (Point of care testing). The tests are used outside of hospital laboratories to enable rapid assessments of the health of patients. The company's POCT platform is under development with the intention of measuring various biomarkers simultaneously. An important component of the work is to reduce the time for test results, particularly important for patients with heart problems. The company was founded in 1999 and is based in Lund.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
Nordic SME
PRLD
Daily low / high price
0.152 / 0.173
SEK
Market cap
117.95M SEK
Turnover
276.65K SEK
Volume
1.7M
Financial calendar
Annual report
21.02.2025
Interim report
14.05.2025
Interim report
28.08.2025
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Steven Andrew Ross | 5.3 % | 5.3 % |
| Aileen McGettrick | 5.3 % | 5.3 % |
| Julie Richards | 5.3 % | 5.3 % |
| Paul Brendan Monagan | 5.3 % | 5.3 % |
| Avanza Pension | 3.9 % | 3.9 % |
| Nordic Underwriting APS | 2.8 % | 2.8 % |
| The Bank of New York Mellon, W9 | 1.9 % | 1.9 % |
| Cardeon AB | 1.6 % | 1.6 % |
| Tuvedalen Limited | 0.8 % | 0.8 % |
| Handelsbanken Livförsäkringsaktiebolag | 0.8 % | 0.8 % |
ShowingAll content types
Emergers: Equity Research | PROLIGHT: Commercial prototype marks an important milestone towards upcoming studies
Prolight achieves significant milestone with arrival of first Psyros™ commercial prototype instruments
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools